Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Body and Mind Inc. ("BAM") Contracts With GPEN

Body and Mind Inc.
Posted on: 12 Apr 18
Body and Mind Inc. ("BAM") Contracts With GPEN Not for Distribution to U.S. News Wire Services or for Dissemination in the U.S.

PR Newswire

VANCOUVER, British Columbia, April 12, 2018

VANCOUVER, British Columbia, April 12, 2018 /PRNewswire/ --

Body and Mind Inc. (CSE: BAMM) (US OTC: BMMJ), (the "Company" or "BAM") is pleased to announce the Company has teamed up with GPEN, a company which is at the forefront of engineering the most advanced, user-friendly portable vaporizers in the world. The Company has entered into a one-year, renewable contract with GPEN and will be one of only two companies currently supplying the GPEN Gio cartridges in the State of Nevada. The Company intends to capitalize on the market by incorporating BAM's recognized flavors into the cartridges.

BAM President Robert Hasman commented, "We're delighted to have signed this collaboration with GPEN, a leader in the vaporizer market. This is further affirmation of the brand strength of BAM as a supplier of premium products, as well as our distribution system throughout the State."

Chris Folkerts, Founder and CEO of GPEN commented, "Our success to date has been choosing the right deployment partners in new markets. As a result, the GPEN products will be available in over 500 dispensaries in the US by calendar year end. Our partnership with BAM has been excellent. Not only do they cultivate premium flower under a quality brand but they have an extensive distribution network that will see our products become more available in Nevada. We are happy to report exceptional reviews so far and we look forward to expanding our relationship with BAM further."

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the inability of the Company to obtain shareholder and exchange approval, or to raise additional equity as well as the various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on . Body and Mind Inc. undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law or the Canadian Securities Exchange. 

We seek safe harbour. 

For further information regarding Body and Mind Inc. please contact:
Darren Tindale

PR Newswire

Last updated on: 12/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.